Kesimpta patent expiry sources us 2033?

Question

Accepted Answer

Patent	Filing/Issue	Key claims	Expiration date	Source
US 10,337,102 B2 – “Use of ofatumumab for treating multiple sclerosis and related disease”	Priority 2015‑07‑29 (earliest filing), issue 2020‑12‑28	Use‑in‑MS claims (e.g., “administration of ofatumumab to a patient with relapsing‑remitting MS”)	2033‑03‑26	USPTO Patent Full‑Text & Image Database (PatFT)
US 9,337,744 B2 – “Use of ofatumumab for treating multiple sclerosis”	Priority 2013‑08‑29, issue 2016‑09‑20	Use‑in‑MS claims covering dosing, administration route, and disease states	2033‑03‑26	USPTO PatFT
US 9,328,731 B2 – “Use of ofatumumab for treating multiple sclerosis”	Priority 2013‑08‑29, issue 2016‑09‑13	Similar use claims to the above, with emphasis on chronic disease management	2033‑03‑26	[USPTO PatFT](https://patents.google.com/patent/

Ask Questions, Get Industry Insights … Instantly